Summit Securities Group’s Maravai LifeSciences MRVI Stock Holding History

Summit Securities Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-969	Closed	-$2.78K	–	1162
2025 Q3	$2.78K	Sell	969 -27,971	-97%	-$71.4K	﹤0.01%	943
2025 Q2	$69.7K	Buy	28,940 +24,713	+585%	+$51.9K	0.01%	430
2025 Q1	$9.34K	Buy	+4,227	New	+$16.7K	﹤0.01%	554
2024 Q4	–	Sell	-3,000	Closed	-$25K	–	810
2024 Q3	$25K	Buy	+3,000	New	+$25.9K	0.01%	315
2024 Q1	–	Sell	-2,000	Closed	-$13K	–	747
2023 Q4	$13K	Hold	2,000	–	–	﹤0.01%	505
2023 Q3	$20K	Sell	2,000 -1,000	-33%	-$11K	﹤0.01%	364
2023 Q2	$37K	Buy	+3,000	New	+$40.5K	﹤0.01%	478

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's MRVI Position: Q4 2025 in Review

Summit Securities Group sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 969 shares — an estimated $2.78K sold.

Summit Securities Group first reported a position in MRVI in Q2 2023 and held it in 7 quarters. The position peaked at $69.7K in Q2 2025. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

Summit Securities Group reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
Summit Securities Group sold 969 Maravai LifeSciences shares in Q4 2025, an estimated $2.78K.
Summit Securities Group first reported a position in Maravai LifeSciences in Q2 2023 and held it in 7 quarters.
Summit Securities Group's Maravai LifeSciences position peaked at $69.7K in Q2 2025.
159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.